What is tirzepatide?
Tirzepatide is a synthetic peptide that acts as a dual agonist at both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. That dual mechanism distinguishes it from earlier single-receptor GLP-1 agonists. In clinical studies, tirzepatide has demonstrated meaningful reductions in body weight in adults with obesity or overweight, with effects attributed to reduced appetite, slowed gastric emptying, and improved insulin sensitivity.
Compounded tirzepatide — the form available through licensed 503A pharmacies in the USA — is a separate preparation from the branded injectable product. Compounded versions are not FDA-approved. They are prepared under a clinician prescription by licensed compounding pharmacies, and their ingredients, including any co-formulated nutrients, must meet the requirements set by the prescribing clinician and the pharmacy.
What is cyanocobalamin?
Cyanocobalamin is a synthetic, stable form of vitamin B12, the water-soluble vitamin essential for DNA synthesis, red blood cell formation, and the maintenance of the myelin sheath protecting nerve fibers. In the body, cyanocobalamin is converted to the active coenzyme forms, methylcobalamin and adenosylcobalamin, which participate directly in these metabolic pathways.
B12 is unique among vitamins in requiring a specialized transporter, intrinsic factor produced by gastric parietal cells, to be absorbed in the small intestine. This absorption mechanism can be disrupted by anything that affects gastric physiology — including changes in gastric motility.
Why do compounding pharmacies add cyanocobalamin to tirzepatide?
The clinical rationale for pairing cyanocobalamin with tirzepatide relates to one of tirzepatide’s core mechanisms: slowed gastric emptying. GLP-1 receptor agonism reduces the rate at which the stomach moves its contents into the small intestine. Over time, altered gastric motility has been associated with changes in the efficiency of intrinsic-factor-mediated B12 absorption in some patients.
This dynamic is already documented with metformin, a different drug class that also appears to affect B12 absorption through gastrointestinal mechanisms. Clinicians prescribing tirzepatide, particularly in longer-term weight management protocols, sometimes opt to include cyanocobalamin in the compounded formulation as a precautionary measure to support B12 status throughout treatment.
A second rationale is nutritional. Patients on calorie-restricted diets during tirzepatide therapy may have reduced total dietary intake, which could include reduced B12 intake from dietary sources such as animal proteins. Co-formulating cyanocobalamin ensures a consistent supplemental dose with each injection, independent of dietary variability.
Adding B12 to the injection delivers a consistent supplemental dose regardless of how much a patient is eating during caloric restriction.
What does cyanocobalamin actually do in the body?
Once absorbed, cyanocobalamin participates in two critical biochemical pathways:
Methionine synthesis
Methylcobalamin (one of the active B12 coenzymes) is required for the enzyme methionine synthase to convert homocysteine to methionine. This reaction also regenerates tetrahydrofolate, linking B12 metabolism to folate metabolism and ultimately to DNA synthesis and methylation reactions throughout the body. Elevated homocysteine, a marker of impaired B12 status, is associated with cardiovascular and neurological risks.
Branched-chain fatty acid metabolism
Adenosylcobalamin (the mitochondrial B12 coenzyme) is a cofactor for methylmalonyl-CoA mutase, which processes certain branched-chain fatty acids and amino acid breakdown products. When B12 is deficient, methylmalonyl-CoA accumulates and is converted to methylmalonic acid (MMA), a clinically useful biomarker of functional B12 deficiency.
Neurological maintenance
B12 is essential for the synthesis and maintenance of the myelin sheath that protects nerve fibers. Long-standing B12 deficiency can cause subacute combined degeneration of the spinal cord, peripheral neuropathy, and cognitive changes. Early deficiency may present as fatigue, paresthesias, or subtle mood shifts before overt neurological signs develop.
How is the tirzepatide cyanocobalamin compound structured?
The specific formulation of a tirzepatide cyanocobalamin compound depends on the prescribing clinician and the compounding pharmacy. Typical considerations include:
- Tirzepatide dose and titration: Weight management protocols typically start at a lower dose and titrate upward over weeks based on patient response and tolerability, following a schedule set by the prescribing clinician.
- Cyanocobalamin amount: The B12 component is dosed to support adequate serum levels without exceeding safe ranges. Because cyanocobalamin is water-soluble, excess is generally excreted, but the specific inclusion amount is a clinician decision.
- Administration route: Subcutaneous injection is standard. The compound is typically prepared as a solution for injection in bacteriostatic water or a similar sterile vehicle.
- Pharmacy standards: Compounded preparations from licensed 503A pharmacies in the USA must meet quality and sterility requirements. Every dose in a PepScribe protocol is compounded in the USA by licensed 503A pharmacies. No hidden overseas supply chain.
Is adding cyanocobalamin to tirzepatide always necessary?
Not necessarily. The decision to include cyanocobalamin in a tirzepatide compound is a clinical judgment call. Clinicians may or may not include it depending on a patient’s baseline B12 levels, dietary patterns, the expected duration of tirzepatide therapy, and any concurrent medications that may affect B12 absorption.
Some clinicians prefer to monitor serum B12 and MMA levels and supplement separately if indicated, rather than including cyanocobalamin in the injection formulation. Others include it proactively. Neither approach is universally correct — it depends on the individual clinical context.
What matters is that the question is asked and considered. A protocol that includes a long-term GLP-1 or dual agonist without any consideration of B12 status is missing an important monitoring dimension.
Compliance and sourcing: what patients should know
Compounded tirzepatide — including tirzepatide cyanocobalamin compounds — is only legally available through licensed 503A compounding pharmacies in the USA with a valid clinician prescription. Obtaining tirzepatide from unregulated online sources, research chemical vendors, or overseas suppliers carries serious risks related to purity, sterility, accurate dosing, and the absence of medical oversight.
Compounded tirzepatide is not FDA-approved and should not be represented as equivalent to the branded injectable product. Patients enrolled in a clinician-supervised program receive a formulation prepared under pharmacy quality standards, dispensed with a valid prescription, and monitored through periodic clinical check-ins.
To explore whether tirzepatide is appropriate for your goals, the first step is a clinical assessment. Learn more about tirzepatide and how PepScribe’s clinician-supervised weight management programs work.
Frequently asked questions
What is a tirzepatide cyanocobalamin compound?
A tirzepatide cyanocobalamin compound is a preparation in which tirzepatide — a dual GIP and GLP-1 receptor agonist used for weight management — is combined with cyanocobalamin (a form of vitamin B12) in a single compounded injection. Licensed 503A compounding pharmacies prepare these formulations based on a clinician prescription.
Why is cyanocobalamin added to tirzepatide?
GLP-1 and dual GIP/GLP-1 agonists can slow gastric motility, which may affect intrinsic-factor-mediated B12 absorption over time. Clinicians sometimes prescribe cyanocobalamin alongside tirzepatide as a supportive nutrient to maintain adequate B12 status during long-term therapy.
Is the tirzepatide cyanocobalamin compound FDA-approved?
No. Compounded tirzepatide — with or without cyanocobalamin — is not FDA-approved. It is a compounded preparation made in licensed 503A pharmacies under a clinician prescription. The branded injectable tirzepatide product is FDA-approved, but compounded versions are separate formulations.
What does cyanocobalamin do in the body?
Cyanocobalamin is converted in the body to active cobalamin coenzymes (methylcobalamin and adenosylcobalamin) that support DNA synthesis, red blood cell formation, and neurological function. Vitamin B12 deficiency can cause fatigue, peripheral neuropathy, and cognitive symptoms.
How is this compound administered?
Compounded tirzepatide cyanocobalamin preparations are typically administered as a subcutaneous injection, following the clinician-prescribed protocol. Dose, frequency, and titration schedule are set by the prescribing clinician based on individual goals and response.
Can I get this compound without a prescription?
No. Compounded tirzepatide formulations require a valid prescription from a licensed clinician. They are prepared by licensed 503A compounding pharmacies in the USA and dispensed only through that legal channel.